DIANTHUS THERAPEUTICS INC (DNTH) Stock Price, Quote, News and Overview
NASDAQ:DNTH - Nasdaq - US2528281080 - Common Stock - Currency: USD
DNTH Quote, Performance and Key Statistics
24.03
+0.51 (+2.17%)
The current stock price of DNTH is 24.03 USD. In the past month the price increased by 4.66%. In the past year, price decreased by -4.38%.
DNTH Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.17 | 378.30B | ||
| AMGN | AMGEN INC | 16.39 | 174.51B | ||
| GILD | GILEAD SCIENCES INC | 25.47 | 146.22B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1683.76 | 125.39B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.5 | 77.34B | ||
| ARGX | ARGENX SE - ADR | 231.21 | 36.10B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.66B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.47B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.08B | ||
| BIIB | BIOGEN INC | 9.13 | 22.01B | ||
| NTRA | NATERA INC | N/A | 19.02B | ||
| GMAB | GENMAB A/S -SP ADR | 24.89 | 15.34B |
Related stock screener links
About DNTH
Company Profile
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. The company is headquartered in New York City, New York and currently employs 53 full-time employees. The company went IPO on 2018-06-21. The firm is dedicated to designing and delivering monoclonal antibodies with improved selectivity and potency. The firm has initiated a Phase 2 trial of DNTH103, a potential active C1s inhibitor, in generalized Myasthenia Gravis and plans to initiate additional Phase 2 trials in other neuromuscular indications, including Multifocal Motor Neuropathy and Chronic Inflammatory Demyelinating Polyneuropathy. Its product candidate, DNTH103, is a clinical-stage, highly potent, highly selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of the C1s complement protein. DNTH103 is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain, and has a pharmacokinetic (PK) profile.
Company Info
DIANTHUS THERAPEUTICS INC
7 Times Square, 43Rd Floor
New York City NEW YORK US
Employees: 53
Company Website: https://dianthustx.com/
Investor Relations: https://investor.magentatx.com/
Phone: 19299994055
DIANTHUS THERAPEUTICS INC / DNTH FAQ
What is the stock price of DIANTHUS THERAPEUTICS INC today?
The current stock price of DNTH is 24.03 USD. The price increased by 2.17% in the last trading session.
What is the ticker symbol for DIANTHUS THERAPEUTICS INC stock?
The exchange symbol of DIANTHUS THERAPEUTICS INC is DNTH and it is listed on the Nasdaq exchange.
On which exchange is DNTH stock listed?
DNTH stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for DIANTHUS THERAPEUTICS INC stock?
18 analysts have analysed DNTH and the average price target is 53.65 USD. This implies a price increase of 123.27% is expected in the next year compared to the current price of 24.03. Check the DIANTHUS THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is DIANTHUS THERAPEUTICS INC worth?
DIANTHUS THERAPEUTICS INC (DNTH) has a market capitalization of 711.29M USD. This makes DNTH a Small Cap stock.
How many employees does DIANTHUS THERAPEUTICS INC have?
DIANTHUS THERAPEUTICS INC (DNTH) currently has 53 employees.
What are the support and resistance levels for DIANTHUS THERAPEUTICS INC (DNTH) stock?
DIANTHUS THERAPEUTICS INC (DNTH) has a support level at 21.66 and a resistance level at 24.03. Check the full technical report for a detailed analysis of DNTH support and resistance levels.
Is DIANTHUS THERAPEUTICS INC (DNTH) expected to grow?
The Revenue of DIANTHUS THERAPEUTICS INC (DNTH) is expected to grow by 139.46% in the next year. Check the estimates tab for more information on the DNTH EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy DIANTHUS THERAPEUTICS INC (DNTH) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of DNTH, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of DNTH, evaluating the profitability, health, valuation and growth aspects
- DIANTHUS THERAPEUTICS INC (DNTH) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- DIANTHUS THERAPEUTICS INC (DNTH) Sales and EPS estimates to see what analysts future expectations are.
- DIANTHUS THERAPEUTICS INC (DNTH) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- DIANTHUS THERAPEUTICS INC (DNTH) Insider and Institutional Ownership to learn about the owners and their transactions.
- DIANTHUS THERAPEUTICS INC (DNTH) Stock Chart to make your own analysis
- DIANTHUS THERAPEUTICS INC (DNTH) Latest news and press-releases to stay up to date.
Does DIANTHUS THERAPEUTICS INC (DNTH) stock pay dividends?
DNTH does not pay a dividend.
When does DIANTHUS THERAPEUTICS INC (DNTH) report earnings?
DIANTHUS THERAPEUTICS INC (DNTH) will report earnings on 2025-03-20, after the market close.
What is the Price/Earnings (PE) ratio of DIANTHUS THERAPEUTICS INC (DNTH)?
DIANTHUS THERAPEUTICS INC (DNTH) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.5).
What is the Short Interest ratio of DIANTHUS THERAPEUTICS INC (DNTH) stock?
The outstanding short interest for DIANTHUS THERAPEUTICS INC (DNTH) is 19.67% of its float. Check the ownership tab for more information on the DNTH short interest.
DNTH Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to DNTH. When comparing the yearly performance of all stocks, DNTH turns out to be only a medium performer in the overall market: it outperformed 41.85% of all stocks.
DNTH Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to DNTH. DNTH has a great financial health rating, but its profitability evaluates not so good.
DNTH Financial Highlights
Over the last trailing twelve months DNTH reported a non-GAAP Earnings per Share(EPS) of -2.5. The EPS increased by 85.88% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -18.94% | ||
| ROE | -19.86% | ||
| Debt/Equity | 0 |
DNTH Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 88% to DNTH. The Buy consensus is the average rating of analysts ratings from 18 analysts.
For the next year, analysts expect an EPS growth of 79.85% and a revenue growth 139.46% for DNTH